Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 5:44 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 581 - 600 ( 667 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Draft Guidance on Serious Conditions Implies Advantage Eteplirsen
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surprise CHMP Decision Establishes the Dire Clinical Need in DMD.
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We initiate SRPT with a BUY rating and a $52 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14 Update-Eteplirsen NDA Filing Anticipated by YE:14 for Potential Accelerated Approval by H2:15
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent FDA DMD Guidance May Put Pressure on EMA for Ataluren?s Conditional Approval - ISIS?s SMA Updates at AAN Informative to PTCT?s Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent FDA DMD Guidance May Put Pressure on EMA for Ataluren?s Conditional Approval - ISIS?s SMA Updates at AAN Informative to PTCT?s Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raising Price Target to $60 - NDA Filing YE:14 - Path Forward Suggests FDA Open to Accelerated Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:13 Update - Follow-on Exons in Clinic by Year End - Product Supply Good to Go - FDA Progress Slow, but Suggestive of Potential New Trial Designs
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L